Navigation Links
GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™
Date:10/25/2010

ORLANDO, Fla., Oct. 25 /PRNewswire/ -- GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today announced that it ranked number 62 on Technology Fast 500, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.  Rankings are based on percentage of fiscal year growth during the period from 2005-2009.  GeneLink grew 2057 percent during this period. GeneLink ranked 17th overall in the Biotechnology/Pharmaceutical sector.

GeneLink's CEO Gary Beeman credits the Company's genetic science and its DNA-guided personalized health products for the dramatic revenue growth.  "GeneLink's growth is a testament to the pioneering research by our scientists over the past decade as well as an indicator of the growing interest in personalized wellness products customized to each individual's DNA."

"GeneLink and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader.  "Deloitte commends GeneLink for this impressive accomplishment."

"GeneLink has proven itself to be one of the fastest growing tech companies in North America, and we are proud to honor them as one of the 2010 Technology Fast 500," said Mark Jensen, managing partner, Venture Capital Services, Deloitte & Touch LLP.

GeneLink previously ranked 92nd in the  Deloitte "Fast 500" in 2008.


About GeneLink:

GeneLink is a wellness company engaged in genetic test and product development.  GeneLink's patented technologies include proprietary genetic assessments and products for personalized health, beauty and wellness.  For information, visit www.genelinkbio.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

As used in this document, "Deloitte" means Deloitte LLP.  Please see www.deloitte.com/us/about  for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.



'/>"/>
SOURCE GeneLink BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink Announces HelixLife Private Label Distribution Agreement
2. GeneLink Reports First Quarter Gains
3. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
4. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
5. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
8. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
9. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
10. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
11. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... A leader in science-based, ... , Nerium International is proud to introduce its Age-Defying Night Cream, NeriumAD™ Formula, ... to consumers across Hong Kong. The luxury skincare products contain innovative ingredients that ...
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting a BioMixer ... at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers are ... opportunity to interact with peers, make new connections and talk bio biz. , Cost:, ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
Breaking Biology Technology:
(Date:2/1/2017)... February 1, 2017 IDTechEx Research, a leading ... technology, announces the availability of a new report, Sensors for ... Continue Reading ... ... collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
Breaking Biology News(10 mins):